Evidence map›Paper›PMID 26856237›Full record

ArticleTrends in molecular medicine2016

Exon Snipping in Duchenne Muscular Dystrophy.

Dwi U Kemaladewi, Ronald D Cohn

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. A Translational Roadmap for Neurological Nonsense Mutation Disorders.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Molecular Therapies for Muscular Dystrophies.Current treatment options in neurology · 2018
    Review
  5. Whole genome sequencing reveals a 7 base-pair deletion in DMD exon 42 in a dog with muscular dystrophy.Mammalian genome : official journal of the International Mammalian Genome Society · 2017
    Article
  6. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2016
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Dwi U KemaladewiGenetics and Genome Biology Program, the Hospital for Sick Children, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Ronald D CohnGenetics and Genome Biology Program, the Hospital for Sick Children, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada; Department of Pediatrics, University of Toronto, Toronto, ON, Canada; Division of Clinical and Metabolic Genetics, the Hospital for Sick Children, Toronto, ON, Canada; Centre for Genetic Medicine, the Hospital for Sick Children, Toronto, ON, Canada. Electronic address: ronald.cohn@sickkids.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a life-limiting neuromuscular disorder caused by mutations in the DMD gene encoding dystrophin. We discuss very recent studies that used CRISPR/Cas9 technology to 'snip out' mutated exons in DMD, restoring the reading frame of the gene. We also present cautionary aspects of translating this exciting technology into clinical practice.

Indexed as

CRISPR-Cas SystemsAnimalsDystrophinExonsGenetic TherapyMaleMuscle, SkeletalMuscular Dystrophy, DuchenneDystrophin

Identifiers

PMID26856237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.